Por primera vez llega a México “Best Of ASTRO 2014”

Oncología.mx.-  Por primera vez es traido a México el “Best Of Astro 2014”, que originalmente se realiza en Estados Unidos por la American Society for Radiation Oncology (ASTRO), el congreso trata de las innovaciones en Radiología y se llevará a cabo en el Auditorio “Dr. Luis Guevara González” de la Unidad Académica de la Fundación Clínica Médica Sur del 27 al 28 de marzo.

Con este evento se busca atender y cubrir las necesidades de salud de los mexicanos a través de 4 grandes pilares: enseñanza, asistencia médica, innovación e investigación, con foros en español e inglés. Los participantes de esta reunión son líderes en el campo de la Radiología.

Programa 27 de Marzo

Registro de 7 a.m. a 5:15 pm

La bienvenida estará a cargo de Julia Angelina Sáenz Frías, Presidenta de la Sociedad Mexicana de Radioterapeutas, A.C.

De 8:00 a.m.a 9:00 a.m-  Adela Poitevin Chacón, del Hospital Médica Sur.

Track 1. Mama, Elizabeth Trejo Durán, Instituto Nacional de Cancerología 

Bernardino Gabriel Santiago Concha, Instituto Nacional de Cancerología 

• Abstract 1 – 294- Long-term Outcomes of Hypofractionation vs. Conventional Radiotherapy Following Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast 

• Abstract 3 – 148- Significance of Phospho(Ser73)-K8 Expression in Women With Breast Cancer of Triple Negative Phenotype 

• Abstract 4 – 299- Prevalence of Arm Symptoms and Arm Swelling in Breast Cancer Patients Treated With Hypofractionated Compared to Conventional Fractionated Nodal Radiation Therapy in the Modern Era of CT-Based RT Planning 

• Abstract 5 – 149- The Influence of Receptor Status on Locoregional Recurrence Risk among Breast Cancer Patients with Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Mastectomy 

• Abstract 6 – 1030- Outcome Following Local-regional Recurrence (LRR) in Women with Early Stage Breast Cancer: Impact of Biologic Subtype 

• Abstract 7 – LBA3- Hypofractionated Whole Breast Irradiation Results In Less Acute Toxicity And Improved Quality Of Life At 6 Months Compared To Conventionally Fractionated Whole Breast Irradiation: Results Of A Randomized Trial 

9:00 a.m. – 9:45 a.m.  Track 2 – Linfoma/Leucemia, Yicel Bautista Hernández, Hospital General de México.

• Abstract 1 – 138- Cardiovascular Diseases after Hodgkin Lymphoma Treatment; 35-year Disease Risk and Sequence of Events 

• Abstract 2 – CT-08- Early-Stage Hodgkin’s Disease: The Utilization of Radiation Therapy and Its Impact on Overall Survival 

• Abstract 3 – 338- Comparison Between the German Hodgkin Study Group (GHSG) Involved Field Radiotherapy (IF-RT) versus the International Lymphoma Radiation Oncology Group (ILROG) Involved Site Radiotherapy (IS-RT) for Patients with Hodgkin’s Lymphoma- Is ISRT the New Standard? 

• Abstract 4 – 145- Improved Outcomes with Radiotherapy in Stage I-II Primary Mediastinal B-Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis 

• Abstract 5 – 334- Low Dose (12 Gy) Total Skin Electron Beam Therapy (tsebt) for Mycosis Fungoides (mf): Results of Three Phase 2 Clinical Trials AND 335- Favorable Outcome in Stage I-II Mantle Cell Lymphoma: A Report of 160 Patients from the International Lymphoma Radiation Oncology Group (ILROG).

De 9:45 a.m. a 10:15 a.m. receso.

De 10:15 a.m. a 11:15 a.m.- Track 3 – Pulmón, Mónika Blake Cerda, Instituto Nacional de Cancerología. 

• Abstract 1 – CT-05- International Multicenter Randomized Study On Thoracic Radiotherapy (TRT) In Extensive Stage Small Cell Lung Cancer (ES-SCLC): Patterns Of Disease Recurrence 

• Abstract 2 – 163- A Gene Expression Platform to Predict Benefit from Adjuvant External Beam Radiation in Resected Non-Small Cell Lung Cancer 

• Abstract 3 – 56- Long-term Results of RTOG 0236: A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Medically Inoperable Stage I Non-Small Cell Lung Cancer 

• Abstract 4 – 317- Residual Post-Treatment FDG Avidity in Regional Lymph Nodes Impacts Local-Regional Control in Patients Receiving Definitive Chemoradiation for Non-Small Cell Lung Cancer: A Secondary Analysis of ACRIN 6668/RTOG 0235 

• Abstract 5 – 323- Definitive Hyperfractionated Accelerated (AHF) Radiochemotherapy (CRT) vs. Neoadjuvant AHF-CRT and Surgery (S) for Patients (pts) with operable Stage IIIA(N2)/selected IIIB Non-Small-Cell Lung Cancer (NSCLC) following Induction Chemotherapy (IND-C): Results from a Multicenter Phase III Study 

• Abstract 6 – 127- Higher Doses to Smaller Volumes Explains Higher Proton Therapy Radiation Pneumonitis Rates Found 

• Abstract 7 – 51- Time Will Tell: Is 60 Gy in 3 Fractions the Optimal SBRT Schedule for Stage I Non-Small Cell Lung Cancer? 

• Abstract 8 – 58- Sbrt for Lung Metastases: A Pooled Analysis of 651 Patients and 868 Lesions of the German Working Group Stereotactic Radiotherapy.

11:15 a.m. – 12:00 p.m. Caso clínico Pregunta y respuesta – Panel 1 

Challenging Case Question and Answer Panels allow attendees to seek expert advice from panel members on challenging patient cases specific to the disease sites previously discussed. Be sure to submit your challenging case questions via the interactive devices. 

Moderadora: Beatriz Améndola M.D., Innovative Cancer Institute, Miami 

Panelistas: 

• Elizabeth Trejo Durán, Instituto Nacional de Cancerología 

• Yicel Bautista Hernández, Hospital General de México 

• Mónika Blake Cerda, Instituto Nacional de Cancerología 

• Bernardino Gabriel Santiago Concha, Instituto Nacional de Cancerología.

12:00 p.m. – 1:00 p.m. Comida

1:00 p.m. – 1:45 p.m. Track 4 – Cuidados paliativos, Ma. Dolores de la Mata Moya , Centro Médico ABC 

• Abstract 1 – 171- Interim Analysis Results Of A Phase II Trial Of Low Dose Radiotherapy For Palliation Of Diffuse Large B Cell Lymphoma 

• Abstract 2 – 172- Patient Reported Outcomes on the Impact of Single versus Multiple Fraction Palliative Radiotherapy for Uncomplicated Bone Metastases on Pain, Function and Degree of Symptom Distress 

• Abstract 3 – 173- A Comparison of Palliative Inpatient Management Strategies For Cancer-Related Superior Vena Cava Obstruction 

• Abstract 4 – 174- Incidence of Pain Flare Following Palliative Radiotherapy for Symptomatic Bone Metastases: Multicenter Prospective Observational Study 

• Abstract 5 – 178- Factors Influencing Vertebral Compression Fracture Specific to Renal Cell Carcinoma Spinal Metastases after Stereotactic Body Radiotherapy: A Multi-Institutional Study.

1:45 p.m. – 2:30 p.m. Track 5 – Seguridad del paciente, Fabiola Flores Vázquez, Centro Médico ABC 

• Abstract 1 – 277- Prospective Dosimetric Data Generation for Every Patient and Fraction to Analyze Results on Radiation Oncology Patient Registries 

• Abstract 2 – 281- Reducing Errors in Radiation Treatment Through the Implementation of Electronic Safety Checklists 

• Abstract 3 – 280- Lessons From a Prospective Incident Learning System: Focus on Physician-Specific “Errors/Near-Misses” and “Errors” that Reached the Patient 

• Abstract 4 – 283- Do Emergent Treatments Result in More Severe Errors? Analysis of a Large Institutional Near-Miss Incident Learning Database 

• Abstract 5 – 278- Review of High-Dose-Rate (HDR) Brachytherapy Plan Errors: Effect of Software-Aided Verification on Effectiveness and Efficiency of the Physics Plan Quality Assurance (QA) Process.

2:30 p.m. – 3:00 p.m. Track 6 – Física, Alejandro Rodríguez Laguna, Hospital Médica Sur 

• Abstract 1 – 45- Pushing the Dose to the Spinal Cord in Spine SBRT – Cord and Thecal Sac Dosimetric Correlation with Toxicity 

• Abstract 2 – 42- First Clinical Implementation of Electromagnetic Transponder-Guided MLC Tracking 

• Abstract 3 – 48- Site-Specific Range Uncertainties Due to by Dose Calculation Algorithms for Proton Therapy 

• Abstract 4 – 46- Dosimetric Evaluation of a Limited-angle Intrafraction Verification (LIVE) System • Abstract 5 – 202- The Dawn Of A New Era: First Ever MR – IGRT Treatments – Initial Experiences And Future Implications.

3:00 p.m. – 3:30 p.m. Receso

Caso clínico Pregunta y respuesta – Panel 2 

Challenging Case Question and Answer Panels allow attendees to seek expert advice from panel members on challenging patient cases specific to the disease sites previously discussed. Be sure to submit your challenging case questions via the interactive devices. 

Moderador: 

M. en C. Patricio Vázquez Fernández, Instituto Nacional de Pediatría 

Panelistas: 

• Ma. Dolores de la Mata Moya, Hospital ABC 

• Fabiola Flores Vázquez, Centro Médico ABC 

• Alejandro Rodríguez Laguna, Hospital Médica Sur.

4:15 p.m. – 5:15 p.m. Sesión Educativa I: Society of Surgical Oncology – American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer (2014) 

• Mariana Chávez Mac Gregor, MD Anderson Cáncer Center, Houston.

Programa 28 de marzo:

 Registro de 7:00 a.m. a 7:55 a.m. 

 Bienvenida de 7:55 a.m. a 8:00 a.m., a cargo de Michelle Aline Villavicencio Queijeiro, Hospital General de México.

8:00 a.m. – 9:00 a.m.- Track 7 – Genitourinario José Hinojosa Gómez, Centro Médico ABC. 

• Abstract 1 – PL-02 – Randomized Phase III Trial of Adjuvant Androgen Deprivation in Combination with High-dose Conformal Radiotherapy in Intermediate and High Risk Localized Prostate Cancer 

• Abstract 2 – 24 – Quality of Life in Patients with Testosterone Recovery after Long Term Androgen Deprivation Therapy for High Risk Prostate Cancer 

• Abstract 3 – 18 – Impact of Node Status and Radiotherapy on Failure-Free Survival in Patients With Newly Diagnosed Non-Metastatic Prostate Cancer: Data From >690 Patients in the Control Arm of the STAMPEDE Trial 

• Abstract 4 – 19 – Radiation Therapy for Clinically Node-Positive Prostate Cancer and Survival: Results from the National Cancer Data Base 

• Abstract 5 – LBA1 – Initial Results of a Phase III Randomized Study of High Dose 3DCRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer (RTOG 0126) 

• Abstract 6 – CT-01 – Adjuvant Radiation, Androgen Deprivation and Docetaxel for High-risk Prostate Cancer Post-prostatectomy: Results of RTOG 0621 

• Abstract 7 – CT-02 – Identification and Validation of the Long Non-Coding RNA Schlap1 as a Prognostic Biomarker in Prostate Cancer 

• Abstract 8 – 288 – The Initial Report of RTOG 0524: Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab with Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer

9:00 a.m. – 9:45 a.m.Track 8 – Gastrointestinal, Bonifacio Ramón Ortega, Hospital Médica Sur.

• Abstract 1 – CT-04- The Initial Report of Local Control on RTOG 0436: A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer Treated without Surgery 

• Abstract 2 – CT-03- Best Practice in Advanced Esophageal Cancer: A Report on TROG 03.01 NCIC CTG ES.2 Multinational Phase III Study in Advanced Esophageal Cancer (OC) Comparing Quality of Life (QoL) and Palliation of Dysphagia in Patients Treated with Radiotherapy (RT) or Chemo-Radiotherapy (CRT) 

• Abstract 3 – 34- Local Excision Versus Total Mesorectal Excision in Patients with Good Response After Neoadjuvant Radiochemotherapy for T2-T3 Low Rectal Cancer: Preliminary Results of the GRECCAR 2 Randomized Phase 3 Trial 

• Abstract 4 – 59- Predictors of Radiotherapy-Related GI Toxicity from Anal Cancer DP-IMRT: Secondary Analysis of RTOG 0529 

• Abstract 5 – 99- Interim Analysis of a Phase II Clinical Trial of Induction Gemcitabine/Capecitabine followed by SABR in Borderline/Locally Advanced Pancreatic Adenocarcinoma

9:45 a.m. – 10:15 a.m. Receso

10:15 a.m. – 11:00 a.m.Track 9 – Ginecológicos, Adriana Alvarado Zermeño, Hospital de Occidente 

• Abstract 1 – 236- Consensus Guidelines for Delineation of Clinical Target Volume for Intensity-Modulated Pelvic Radiotherapy in Postoperative Treatment of Endometrial and Cervical Cancer -An Update 

• Abstract 2 – 200- On-Treatment Serum Squamous Cell Carcinoma Antigen (SCCA) Predicts Response to Therapy on Post-Therapy FDG-PET and Recurrence in Women Treated With Chemoradiation for Squamous Cancer of the Cervix 

• Abstract 3 – 198- Expression of DNA Damage Response Proteins in Cervical Cancer Patients Treated With Radical Chemoradiotherapy 

• Abstract 4 – 196- Dose and Volume Response for Local Control in Locally Advanced Cervical Cancer Treated With EBRT Combined With MRI Guided Adaptive Brachytherapy 

• Abstract 5 – 242- Prognostic Factors and Outcome for HPV and Non-HPV Related SCC of the Vulva Treated with Radiotherapy

11: 00 a.m. – 11:30 a.m.Track 10 – Biología, Jesús Manuel Flores Castro, Instituto Nacional de Cancerologia

• Abstract 1 –115- Using Mouse Genetics to Dissect the Radiobiology of SBRT: Tumor Cells, Not Endothelial Cells, Regulate Local Control 

• Abstract 2 – 219- Integrative Radiogenomic Profiling Identifies BRAF Mutations as Novel Radiotherapeutic Targets in Adenocarcinomas of the Lung 

• Abstract 3 – 70- Maternal Embryonic Leucine Zipper Kinase (MELK): A Novel Target for Radiosensitization That is Independently Prognostic in Triple-Negative Breast Cancers

• Abstract 4 – 189- Somatic ERCC2 Mutations Confer Cisplatin Sensitivity in Muscle-Invasive Urothelial Cancer

• Abstract 5 – PL-01- Role of Radiotherapy in Inducing Antigen Specific Anti-Tumor Immune Responses When Combined With Anti-PD1 Checkpoint Blockade: Mechanism and Clinical Implications

11:30 a.m. – 12:15 p.m.- Caso clínico Pregunta y respuesta – Panel 3. 

Case Question and Answer Panels allow attendees to seek expert advice from panel members on challenging patient cases specific to the disease sites previously discussed. Be sure to submit your challenging case questions via the interactive devices. 

Moderador: Jesús Armando Felix Leyva, Centro Médico Nacional Siglo XXI 

Panelistas: 

• José Hinojosa Gómez, Centro Médico ABC 

• Bonifacio Ramón Ortega, Hospital Médica Sur

• Adriana Alvarado Zermeño, Hospital de Occidente 

• Jesús Manuel Flores Castro, Instituto Nacional de Cancerologia

12:15 p.m. – 1:15 p.m. Comida

1:15 p.m. – 2:15 p.m. Track 11 – Sistema Nervioso Central, Luis Héctor Bayardo López, Hospital de Occidente 

• Abstract 1 – 74- Mature Survival Data from RTOG 9802: A Phase III Study of Radiation Therapy (RT) With or Without Procarbazine, CCNU, and Vincristine (PCV) for Adult Patients with High-Risk Low-Grade Glioma (LGG) 

• Abstract 2 – 80- Identification of a 12-gene Expression Signature from the Cancer Genome Atlas Prognostic for Survival in Glioblastoma 

• Abstract 3 – 78- Molecular Stratification of Elderly Patients with Glioblastoma (GBM) Identifies a Subgroup with a Favorable Prognosis 

• Abstract 4 – 272- Radiculopathy or Plexopathy Associated with High Dose Stereotactic Radiosurgery of Spinal Metastasis 

• Abstract 5 – 1022- Hypofractionated (HRT) Vs. Standard (SRT) Radiotherapy With Or Without Temozolomide (T) For Elderly Patients With Glioblastoma (GBM) 

• Abstract 6 – 275- A Multi-Institutional Predictive Nomogram for Distant Brain Failure in Patients Treated with Upfront Stereotactic Radiosurgery without Whole Brain Radiotherapy 

• Abstract 7 – 270- De Novo vs. Progression of an Existing Vertebral Compression Fracture (VCF) Following Spine Stereotactic Body Radiotherapy (SBRT): Separate Risk Profiles to Consider 

• Abstract 8 – 269- Salvage Spine Stereotactic Body Radiotherapy (SBRT) for Spinal Metastases That Failed Initial SBRT: A First Report

2:15 p.m. – 3:15 p.m. Track 12 – Cabeza y cuello, Samuel Rosales Pérez, CMN Siglo XXI 

• Abstract 1- 215- Refining UICC TNM Stage and Prognostic Groups for HPV-Related Oropharyngeal Carcinomas 

• Abstract 2 – 218- Long-Term Quality of Life (QOL) After Chemo-IMRT for Locally Advanced Oropharyngeal Cancer (OPC): A Prospective Longitudinal Study 

• Abstract 3 – 268- Functional Outcomes with Surgical and Non-surgical Management of Locally Advanced Oropharyngeal Cancer 

• Abstract 4 – 267- Risk Factors for Locoregional Recurrence after Transoral Robotic Surgery for HPV+ Oropharyngeal Squamous Cell Carcinoma 

• Abstract 5 – 266- Dose-Escalated Stereotactic Radiosurgery (SRS) Boost for Unfavorable Locally Advanced Oropharyngeal Cancer, Phase I/II Trial 

• Abstract 6 – 212- Survival Outcomes of Patients With T4a Larynx Cancer Following Initial Management With Surgery Vs. Larynx Preservation Therapy 

• Abstract 7 – 1055- Potential Cure in HPV-related Oropharyngeal Cancer with Oligometastases

3:15 p.m. – 3:30 p.m. Receso

3:30 p.m. – 4:15 p.m.- Caso clínico Pregunta y respuesta –Panel 4. 

 Challenging Case Question and Answer Panels allow attendees to seek expert advice from panel members on challenging patient cases specific to the disease sites previously discussed. Be sure to submit your challenging case questions via the interactive devices. 

Moderador:

•F. Guedea Edo, España 

Panelistas: 

•Luis Héctor Bayardo López, Hospital de Occidente 

•Samuel Rosales Pérez, Centro Médico Nacional Siglo XXI

4:15 p.m. – 5:15 p.m. Sesión educativa II: Comunicación Multidisciplinaria, Fis. Miguel Ángel Pérez Pastenes, Hospital Médica Sur.

Clausura a las 5:15 p.m.


Acerca Redacción

También te puede interesar

“¡Autoexplórate y ve un paso adelante contra el cáncer de mama!

Coppel Comunidad se une al movimiento mundial de lucha contra el cáncer de mama con …

Deja un comentario

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *